Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
September 04 2018 - 8:00AM
As a follow up to its July 17, 2018 news release, Resverlogix Corp.
(“Resverlogix” or the “Company”) (RVX:TSX) announced today that it
has presented at the first Clinical Trials in Alzheimer’s Disease
(CTAD) Asia conference in Shanghai, China, this past weekend. Dr.
Jeffrey Cummings, Founding Director of the Cleveland Clinic Lou
Ruvo Brain Health Center, Las Vegas, Nevada, delivered a keynote
presentation on the design and baseline characteristics of a
pre-specified substudy of cognition in elderly patients in the
Company’s ongoing Phase 3 BETonMACE clinical trial. In addition, a
poster presentation highlighted potential Mechanism of Action of
apabetalone in addressing vascular dementia.
"Apabetalone has the potential to confirm a new
hypothesis of BET inhibition and its impact on vascular cognitive
impairment (VCI), dementia and Alzheimer’s disease,” stated Dr.
Cummings. “These new and previously reported data on impact in the
biological areas of neuro inflammation and complement biology
potentially provide us a new approach for the millions of patients
with VCI, dementia and Alzheimer’s patients.”
Proteomics from the Company’s Phase 2 ASSURE
clinical trial highlighted proteins linked to cognitive decline and
neurodegenerative disease favourably affected by apabetalone
treatment, including but not limited to ATP5O, HSPD1, APP,
HSP90AB1, HSP90AA1, HSPA8, ANXA1, EEF1B2, RTN4R, ATP5B and APCS
(p<0.05). These serum proteins have been reported to play a
potential role in impacting neuro plasticity, blood brain barrier
integrity and mitochondrial function, all reported risk markers for
neurodegeneration. The Company will continue its pursuit in further
elucidating these and other proteins that are known to drive
neurovascular risk.
Resverlogix intends to present further data from
its Phase 3 BETonMACE clinical trial at upcoming conferences to
continue to build on the potential of BET inhibition and establish
awareness of this novel approach for vascular cognitive impairment
and dementia.
BETonMACE is a Phase 3 cardiovascular event
outcomes trial in approximately 2,425 high-risk cardiovascular
patients with type II diabetes mellitus. A pre-specified
subpopulation in the trial is comprised of patients 70 years of age
and over. For this patient cohort, Resverlogix is performing the
Montreal Cognitive Assessment (“MoCA”) at Baseline, week 52, week
104 and at the end of the trial. Approximately 450 patients will be
assessed in this whole group of which approximately half have a
MoCA of ≤25, deemed to have mild cognitive impairment.
The BETonMACE trial is expected to be complete
by the end of 2018 with the topline results expected shortly
thereafter.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208),
a first-in-class, small molecule that is a selective BET
(bromodomain and extra-terminal) inhibitor. BET bromodomain
inhibition is an epigenetic mechanism that can regulate
disease-causing genes. Apabetalone is a BET inhibitor selective for
the second bromodomain (BD2) within the BET proteins. This
selective inhibition of apabetalone on BD2 produces a specific set
of biological effects with potentially important benefits for
patients with high-risk cardiovascular disease, diabetes mellitus,
chronic kidney disease, end-stage renal disease treated with
hemodialysis, neurodegenerative disease, Fabry disease, peripheral
artery disease and other orphan diseases, while maintaining a well
described safety profile.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
For further information please contact:
Investor Relations Email: ir@resverlogix.com
Phone: 403-254-9252Or visit our website: www.resverlogix.com
Forward-Looking StatementsThis
news release may contain certain forward-looking information as
defined under applicable Canadian securities legislation, that are
not based on historical fact, including without limitation
statements containing the words "believes", "anticipates", "plans",
"intends", "will", "should", "expects", "continue", "estimate",
"forecasts" and other similar expressions. In particular, this news
release includes forward looking information relating to, and the
potential role of apabetalone in the treatment of CVD, DM, chronic
kidney disease, end-stage renal disease treated with hemodialysis,
neurodegenerative disease, Fabry disease, peripheral artery disease
and other orphan diseases. Our actual results, events or
developments could be materially different from those expressed or
implied by these forward-looking statements. We can give no
assurance that any of the events or expectations will occur or be
realized. By their nature, forward-looking statements are subject
to numerous assumptions and risk factors including those discussed
in our Annual Information Form and most recent MD&A which are
incorporated herein by reference and are available through SEDAR at
www.sedar.com. The forward-looking statements contained in this
news release are expressly qualified by this cautionary statement
and are made as of the date hereof. The Company disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Resverlogix (TSX:RVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Resverlogix (TSX:RVX)
Historical Stock Chart
From Apr 2023 to Apr 2024